Biohaven (BHVN) Net Cash Flow Growth (1y) (2022 - 2026)

Biohaven (BHVN) Net Cash Flow Growth (1y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 172.72%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 53.21%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 75.60%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 1,421.76%
7 Royalty Pharma 33.72 Bn 35.84 Bn - 149.49%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -100.75%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -104.22%
10 Biohaven 2.21 Bn 1.94 Bn - -154.98%

Historic Data

Download Data
DateValue
Jun 30, 2026 -154.98%
Mar 31, 2026 35,633.87%
Dec 31, 2025 207.55%
Sep 30, 2025 112.56%
Jun 30, 2025 19.77%
Mar 31, 2025 100.19%
Dec 31, 2024 -88.58%
Sep 30, 2024 -103.24%
Jun 30, 2024 380.77%
Mar 31, 2024 -25.28%
Dec 31, 2023 -33.72%
Sep 30, 2023 -376.48%
Jun 30, 2023 167.58%
Mar 31, 2023 -44.33%
Dec 31, 2022 166.78%